Kratak video sažetak opisa autoimunih nuspojava imunoterapije i stvarni primjer pristupa.

Nuspojave imunoterapije i njihovo zbrinjavanje

Sadržaj predavanja možete pogledati i u prezentaciji u nastavku.

<ol>
<li>Champiat S et al, Ann Oncol 2016</li>
<li style="font-weight: 400;" aria-level="1">Wolchock J, et al. J Clin Oncol 2013: 31 (issue 15_suppl) abstr9012</li>
<li style="font-weight: 400;" aria-level="1">Marc S. Ernstoff, MD: Presentation at the ASCO 2018, annual meeting.</li>
<li style="font-weight: 400;" aria-level="1">Nature Reviews Clinical Oncology Volume: 13,  Pages: 473–486 Year published: 2016</li>
<li style="font-weight: 400;" aria-level="1">Nat Rev Clin Oncol. 2019 Sep;16(9):563-580</li>
<li style="font-weight: 400;" aria-level="1">NCCN guidelines, NCCN.org version 1, 2018</li>
<li style="font-weight: 400;" aria-level="1">Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, november 2017</li>
<li style="font-weight: 400;" aria-level="1">S. Champiat et al, Management of immune checkpoint blockade</li>
<li style="font-weight: 400;" aria-level="1">Dysimmune toxicities: a collaborative position paper; Annals of Oncology 27: 559–574, 2016</li>
<li style="font-weight: 400;" aria-level="1">Keytruda PI., Melanoma KN001, KN002, KN006, Lung KN001</li>
<li style="font-weight: 400;" aria-level="1">Naidoo JN, J Clin Oncol 2016 (e-published)</li>
<li style="font-weight: 400;" aria-level="1">Survival and Corticosteroid use to manage Immune-mediated AEs, E. Leight, presented at WCLC 2015</li>
</ol>

Autor/i

Završite tečaj i osvojite bodove

Nuspojave imunoterapije i njihovo zbrinjavanje

Reference

Koristite Mediately aplikaciju

Koristite Mediately aplikaciju